CRISPR Therapeutics AG
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Thomas R. SuozziHouse · D · NY |
CRSPCRISPR Therapeutics AG · Stock |
Sale $50,001 - $100,000 |
Oct 5, 2021 | Sep 20, 2021 | Filing ↗ |
Thomas R. SuozziHouse · D · NY |
CRSPCRISPR Therapeutics AG · Stock |
Purchase $50,001 - $100,000 |
Sep 23, 2021 | Jun 3, 2021 | Filing ↗ |
Marjorie Taylor GreeneHouse · R · GA |
CRSPCRISPR Therapeutics AG · Stock |
Purchase $1,001 - $15,000 |
Feb 19, 2021 | Jan 21, 2021 | Filing ↗ |
James M InhofeSenate · R · OK |
CRSPCRISPR Therapeutics AG · Stock |
Sale $1,001 - $15,000 |
Jan 15, 2021 | Jan 5, 2021 | Filing ↗ |
James M InhofeSenate · R · OK |
CRSPCRISPR Therapeutics AG · Stock |
Sale $50,001 - $100,000 |
Dec 23, 2020 | Dec 22, 2020 | Filing ↗ |
James M InhofeSenate · R · OK |
CRSPCRISPR Therapeutics AG · Stock |
Sale $15,001 - $50,000 |
Jun 20, 2018 | Jun 19, 2018 | Filing ↗ |
James M InhofeSenate · R · OK |
CRSPCRISPR Therapeutics AG · Stock |
Purchase $15,001 - $50,000 |
Nov 8, 2017 | Oct 19, 2017 | Filing ↗ |
Whale Activity
- Increased170
- New52
- Held124
- Decreased131
- Closed63
- No prior filing27
| Filer | Shares | Value | Change |
|---|---|---|---|
| ARK Investment Management LLC | 10.1M | $556.3M | increased |
| BlackRock, Inc. | 8.3M | $459.1M | decreased |
| STATE STREET CORP | 5.0M | $276.3M | increased |
| Capital World Investors | 4.7M | $262.2M | decreased |
| Orbis Allan Gray Ltd | 4.5M | $250.0M | decreased |
| GSK plc | 2.6M | $144.3M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5M | $139.0M | increased |
| SR ONE CAPITAL MANAGEMENT, LP | 2.0M | $112.8M | held |
| TWO SIGMA INVESTMENTS, LP | 2.0M | $111.5M | increased |
| FMR LLC | 1.9M | $104.9M | decreased |
| BANK OF AMERICA CORP /DE/ | 1.7M | $96.2M | increased |
| T. Rowe Price Investment Management, Inc. | 1.7M | $91.7M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Kulkarni SamarthChief Executive Officer · Director | Sale | −47.8K | $49.78 | $2.4M | Oct 19, 2026 | Form 4 ↗ |
| George SimeonDirector · Director | Sale | −14.5K | $49.63 | $720K | Oct 14, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Sale | −1,040 | $49.26 | $51K | Oct 14, 2026 | Form 4 ↗ |
| Kulkarni SamarthChief Executive Officer · Director | Sale | −4,098 | $49.26 | $202K | Oct 14, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Sale | −1,990 | $60.04 | $119K | Oct 6, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Sale | −10.4K | $60.24 | $626K | Sep 22, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Option exercise | +10.4K | $13.62 | $142K | Sep 22, 2026 | Form 4 ↗ |
| Behbahani AliDirector | Sale | −13.7K | $57.09 | $781K | Sep 17, 2026 | Form 4 ↗ |
| Behbahani AliDirector | Option exercise | +30.0K | $14.00 | $420K | Sep 17, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Gift | −750 | $0.00 | $0 | Aug 7, 2026 | Form 4 ↗ |
| Patel NaimishChief Medical Officer | Sale | −3,786 | $55.62 | $211K | May 29, 2026 | Form 4 ↗ |
| Patel NaimishChief Medical Officer | Option exercise | +10.0K | — | — | May 28, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Sale | −3,182 | $46.78 | $149K | Mar 23, 2026 | Form 4 ↗ |
| Kulkarni SamarthChief Executive Officer · Director | Sale | −10.0K | $46.78 | $469K | Mar 23, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Sale | −3,708 | $46.78 | $173K | Mar 23, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Option exercise | +6,250 | — | — | Mar 20, 2026 | Form 4 ↗ |
| Kulkarni SamarthChief Executive Officer · Director | Option exercise | +19.7K | — | — | Mar 20, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Option exercise | +6,250 | — | — | Mar 20, 2026 | Form 4 ↗ |
| Patel NaimishChief Medical Officer | Sale | −3,150 | $48.26 | $152K | Mar 16, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Gift | −750 | $0.00 | $0 | Mar 16, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $60.4M | 0.06% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 534.2K | $30.4M | 0.17% | Aug 31, 2026 |
| Avantis U.S. Small Cap Equity ETF American Century ETF Trust | 151.4K | $8.6M | 0.28% | Aug 31, 2026 |
| Nuveen Small Cap Blend Index Fund TIAA-CREF Funds | 121.6K | $5.8M | 0.14% | Jul 31, 2026 |
| Empower T. Rowe Price Mid Cap Growth Fund EMPOWER FUNDS, INC. | 87.3K | $4.8M | 0.25% | Sep 30, 2026 |
| VANGUARD RUSSELL 2000 VALUE INDEX FUND VANGUARD SCOTTSDALE FUNDS | 75.9K | $4.3M | 0.30% | Aug 31, 2026 |
| VANGUARD TOTAL WORLD STOCK INDEX FUND VANGUARD INTERNATIONAL EQUITY INDEX FUNDS | 75.4K | $3.6M | 0.00% | Jul 31, 2026 |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 68.3K | $3.3M | 0.66% | Jul 31, 2026 |
| Nuveen Equity Index Fund TIAA-CREF Funds | 67.2K | $3.2M | 0.01% | Jul 31, 2026 |
| iShares Genomics Immunology and Healthcare ETF iShares Trust | 62.2K | $3.0M | 1.57% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CRSP's shares (CUSIP H17182108), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 17.5K shares0.0%
Nov 16, 2026 · ↗ - ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 4.5M shares4.7%
Nov 16, 2026 · ↗ - Catherine D. WoodSCHEDULE 13G/A · passive (13G) · 10.1M shares10.4%
Nov 13, 2026 · ↗ - ARK Investment Management LLCSCHEDULE 13G/A · passive (13G) · 10.1M shares10.4%
Nov 13, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 5.0M shares5.2%
Nov 10, 2026 · ↗ - Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 15.8K shares0.0%
Aug 14, 2026 · ↗ - ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 5.4M shares5.6%
Aug 14, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 8.0M shares8.3%
Jul 27, 2026 · ↗ - Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 15.8K shares0.0%
May 15, 2026 · ↗ - ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 6.1M shares6.3%
May 15, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming CRISPR Therapeutics AG as the client.
Government Contracts
No federal contract awards found for CRISPR Therapeutics AG.
U.S. Patents
No USPTO patent applications found for CRISPR Therapeutics AG.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M |
| Operating income | -$664.6M | -$466.6M | -$222.5M | -$673.2M | $373.5M |
| Net income | -$581.6M | -$366.3M | -$153.6M | -$650.2M | $377.7M |
| Diluted EPS | -$6.47 | -$4.34 | -$1.94 | -$8.36 | $4.70 |
| Operating cash flow | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M |
| Cash and equivalents | $347.6M | $298.3M | $389.5M | $211.9M | $923.0M |
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M |
| Shareholders' equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B |
As CRISPR Therapeutics AG tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 12, 2026 ↗
Stock Splits
No stock splits in CRSP's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeOct 19, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.03, 5.07, 9.01Officer / director change · Bylaw amendment · Shareholder voteJun 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 4, 2026
EDGAR ↗



